Pfizer Corporation

Abbott Laboratories Corporation

Mikel Paul Moyer

Lee Daniel Arnold

Susan Beth Sobolov-Jaynes

Yat Sun Or

Jay R Luly

Takushi Kaneko

Rodney C Schnur

Jotham Wadsworth Coe

Megumi Kawai

Paul E Wiedeman

Randall James Gallaschun

James W McFarland

Fused bicyclic pyrimidine derivatives

The present invention relates to heterocyclic ring-fused pyrimidine derivatives of formula (I) or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof, wherein Z and Y are as defined in the specification. Compounds of formula (I) are useful in the treatment of hyperproliferative diseases, such as cancers and acnes, in mammals:

Heterocyclic ring-fused pyrimidine derivatives

This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).

Compounds enhancing antitumor activity of other cytotoxic agents

Ansamycin derivatives as antioncogene and anticancer agents

Quinoline derivatives as immunostimulants

Anaphylatoxin-receptor ligands

Growing community of inventors

Clinton, CT, United States of America

Mikel Paul Moyer